Taysha Gene Therapies, Inc. (TSHA) Current Ratio
- Current ratio · latest quarter: Value 17.76×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 17.76× | Current assets / current liabilities. $461.43M ÷ $25.98M ≈ 17.76× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 461.43M USD | Assets, Current |
| Current obligations | 25.98M USD | Liabilities, Current |
| Cash and equivalents | 455.41M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 9.16M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $461.43M | $25.98M | $455.41M | (m) | (m) | (m) | $9.16M | (m) | 17.76× |
| 2026-03-31 | $282.25M | $20.10M | $276.58M | (m) | (m) | (m) | $4.56M | (m) | 14.04× |
| 2025-12-31 | $324.65M | $26.55M | $319.77M | (m) | (m) | (m) | $6.28M | (m) | 12.23× |
| 2025-09-30 | $299.95M | $28.63M | $297.34M | (m) | (m) | (m) | $5.44M | (m) | 10.48× |
| 2025-06-30 | $316.26M | $25.35M | $312.76M | (m) | (m) | (m) | $7.71M | (m) | 12.48× |
| 2025-03-31 | $120.71M | $22.56M | $116.59M | (m) | (m) | (m) | $4.33M | (m) | 5.35× |
| 2024-12-31 | $142.13M | $26.23M | $139.04M | (m) | (m) | (m) | $3.59M | (m) | 5.42× |
| 2024-09-30 | $161.56M | $29.34M | $157.69M | (m) | (m) | (m) | $4.93M | (m) | 5.51× |
| 2024-06-30 | $178.47M | $34.18M | $172.74M | (m) | (m) | (m) | $8.72M | (m) | 5.22× |
| 2024-03-31 | $130.60M | $38.64M | $123.98M | (m) | (m) | (m) | $10.38M | (m) | 3.38× |
| 2023-12-31 | $149.87M | $36.76M | $143.94M | (m) | (m) | (m) | $6.37M | (m) | 4.08× |
| 2023-09-30 | $171.81M | $180.45M | $164.28M | (m) | (m) | (m) | $7.52M | (m) | 0.95× |
| 2023-06-30 | $54.12M | $50.64M | $45.08M | (m) | (m) | (m) | $10.77M | (m) | 1.07× |
| 2023-03-31 | $72.36M | $54.45M | $63.42M | (m) | (m) | (m) | $9.00M | (m) | 1.33× |
| 2022-12-31 | $96.42M | $62.79M | $87.88M | (m) | (m) | (m) | $10.95M | (m) | 1.54× |
| 2022-09-30 | $43.00M | $33.14M | $34.31M | (m) | (m) | (m) | $15.25M | (m) | 1.30× |
| 2022-06-30 | $76.83M | $42.95M | $66.24M | (m) | (m) | (m) | $23.97M | (m) | 1.79× |
| 2022-03-31 | $106.89M | $48.62M | $96.63M | (m) | (m) | (m) | $22.00M | (m) | 2.20× |
| 2021-12-31 | $159.60M | $51.75M | $149.10M | (m) | (m) | (m) | $21.76M | (m) | 3.08× |
| 2021-09-30 | $197.17M | $43.21M | $188.78M | (m) | (m) | (m) | $22.05M | (m) | 4.56× |
| 2021-06-30 | $207.30M | $28.39M | $197.37M | (m) | (m) | (m) | $6.36M | (m) | 7.30× |
| 2021-03-31 | $239.63M | $18.96M | $228.68M | (m) | (m) | (m) | $4.08M | (m) | 12.64× |
| 2020-12-31 | $257.88M | $7.13M | $251.25M | (m) | (m) | (m) | $1.99M | (m) | 36.17× |
| 2020-09-30 | $279.24M | $11.62M | $278.63M | (m) | (m) | (m) | $8.84M | (m) | 24.02× |
| 2019-12-31 | $15.00K | $150.00K | (m) | (m) | (m) | (m) | (m) | (m) | 0.10× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |